SDTM001 injection after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an injection called SDTM001 as an extra treatment after surgery for people with non-small cell lung cancer (NSCLC). It aims to see if it can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You were diagnosed with stage IIA to IIIB non-small cell lung cancer (NSCLC) and had surgery to remove all visible cancer.
- Your cancer cells didn't have certain gene changes (like EGFR or ALK), and your PD-L1 test was negative.
- You have already had 1 to 4 cycles of platinum-based chemotherapy after surgery.
- You are in good general health (ECOG score 0 or 1) and your blood counts and organ function are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial is looking at whether using a sensitive blood test to find tiny bits of cancer left after surgery can help guide whether extra treatment is needed. The goal is to see if this approach is better than standard care for early-stage lung cancer patients.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.